SG10201604605VA - Anti-il-23 antibodies - Google Patents
Anti-il-23 antibodiesInfo
- Publication number
- SG10201604605VA SG10201604605VA SG10201604605VA SG10201604605VA SG10201604605VA SG 10201604605V A SG10201604605V A SG 10201604605VA SG 10201604605V A SG10201604605V A SG 10201604605VA SG 10201604605V A SG10201604605V A SG 10201604605VA SG 10201604605V A SG10201604605V A SG 10201604605VA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41015810P | 2010-11-04 | 2010-11-04 | |
US41195310P | 2010-11-10 | 2010-11-10 | |
US41259410P | 2010-11-11 | 2010-11-11 | |
US201161448785P | 2011-03-03 | 2011-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201604605VA true SG10201604605VA (en) | 2016-07-28 |
Family
ID=44936573
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201604605VA SG10201604605VA (en) | 2010-11-04 | 2011-11-02 | Anti-il-23 antibodies |
SG2013031745A SG190006A1 (en) | 2010-11-04 | 2011-11-02 | Anti-il-23 antibodies |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013031745A SG190006A1 (en) | 2010-11-04 | 2011-11-02 | Anti-il-23 antibodies |
Country Status (39)
Country | Link |
---|---|
US (5) | US8778346B2 (fr) |
EP (4) | EP2635601B1 (fr) |
JP (3) | JP6126532B2 (fr) |
KR (2) | KR101931591B1 (fr) |
CN (2) | CN107522784B (fr) |
AP (1) | AP3953A (fr) |
AR (1) | AR083747A1 (fr) |
AU (3) | AU2011323426B2 (fr) |
BR (1) | BR112013011065B1 (fr) |
CA (2) | CA3017116A1 (fr) |
CO (1) | CO6801628A2 (fr) |
CY (2) | CY1118014T1 (fr) |
DK (1) | DK2635601T3 (fr) |
EA (2) | EA201890548A1 (fr) |
EC (1) | ECSP13012649A (fr) |
ES (1) | ES2593754T3 (fr) |
GE (1) | GEP201706733B (fr) |
HK (1) | HK1247940A1 (fr) |
HR (1) | HRP20161141T1 (fr) |
HU (2) | HUE030916T2 (fr) |
IL (2) | IL225648A (fr) |
LT (2) | LT2635601T (fr) |
LU (1) | LUC00132I2 (fr) |
MA (1) | MA34641B1 (fr) |
ME (1) | ME02499B (fr) |
MX (3) | MX343858B (fr) |
MY (1) | MY162791A (fr) |
NL (1) | NL301013I2 (fr) |
NO (1) | NO2019038I1 (fr) |
NZ (1) | NZ610592A (fr) |
PE (1) | PE20141162A1 (fr) |
PL (1) | PL2635601T3 (fr) |
PT (1) | PT2635601T (fr) |
RS (1) | RS55161B1 (fr) |
SG (2) | SG10201604605VA (fr) |
SI (1) | SI2635601T1 (fr) |
TW (2) | TWI545133B (fr) |
UY (1) | UY33703A (fr) |
WO (1) | WO2012061448A1 (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
WO2012061448A1 (fr) | 2010-11-04 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Anticorps anti-il-23 |
EP4039275A1 (fr) * | 2012-05-03 | 2022-08-10 | Boehringer Ingelheim International GmbH | Anticorps anti-il-23p19 |
TWI636063B (zh) * | 2013-03-08 | 2018-09-21 | 美國禮來大藥廠 | 結合il-23之抗體 |
CN105209064A (zh) | 2013-03-15 | 2015-12-30 | 美国安进公司 | 使用抗il-23抗体治疗银屑病的方法 |
NZ712294A (en) | 2013-03-15 | 2020-04-24 | Amgen Inc | Methods for treating crohn’s disease using an anti-il23 antibody |
US10507241B2 (en) | 2014-07-24 | 2019-12-17 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of IL-23A related diseases |
TWI711629B (zh) * | 2014-09-03 | 2020-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向IL-23A與TNF-α之化合物及其用途 |
CA2972995A1 (fr) * | 2015-02-04 | 2016-08-11 | Boehringer Ingelheim International Gmbh | Methodes de traitement de maladies inflammatoires |
EP3283109A1 (fr) | 2015-04-14 | 2018-02-21 | Boehringer Ingelheim International GmbH | Méthodes de traitement de maladies |
MX2018000959A (es) * | 2015-07-23 | 2018-06-06 | Boehringer Ingelheim Int | Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos. |
US11016099B2 (en) * | 2015-09-17 | 2021-05-25 | Amgen Inc. | Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers |
TWI733695B (zh) * | 2015-09-18 | 2021-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
EP4046655A1 (fr) * | 2015-11-03 | 2022-08-24 | Janssen Biotech, Inc. | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
CN108472367A (zh) | 2015-12-22 | 2018-08-31 | 美国安进公司 | 作为对il23拮抗剂的临床应答的预测因子的ccl20 |
EP3744733A3 (fr) | 2016-04-15 | 2021-02-24 | Boehringer Ingelheim International GmbH | Procédés de traitement de maladies inflammatoires |
US20180105588A1 (en) * | 2016-10-14 | 2018-04-19 | Boehringer Ingelheim International Gmbh | Methods of treating diseases |
CA3090479A1 (fr) * | 2018-02-05 | 2019-08-08 | Tesaro, Inc | Formulations pediatriques de niraparib et procedes de traitement pediatrique |
TWI744617B (zh) * | 2018-03-30 | 2021-11-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
CA3105598A1 (fr) | 2018-07-13 | 2020-01-16 | Carl GOMMOLL | Traitement de la rectocolite hemorragique au moyen de brazikumab |
CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
CN109810947B (zh) * | 2019-01-18 | 2021-06-11 | 北京贝来生物科技有限公司 | 一种抑制Th17细胞活化的间充质干细胞及其制备方法和应用 |
WO2020212874A1 (fr) * | 2019-04-15 | 2020-10-22 | Sun Pharma Global Fze | Procédés de traitement de sujets atteints d'arthrite psoriasique |
WO2021126435A1 (fr) * | 2019-12-20 | 2021-06-24 | Novarock Biotherapeutics, Ltd. | Anticorps anti-interleukine-23 p19 et leurs méthodes d'utilisation |
CN111956606B (zh) * | 2020-08-31 | 2021-05-14 | 江苏荃信生物医药有限公司 | 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂 |
AR123477A1 (es) | 2020-09-10 | 2022-12-07 | Lilly Co Eli | Formulaciones de anticuerpos terapéuticos |
KR20230086765A (ko) | 2020-10-13 | 2023-06-15 | 얀센 바이오테크 인코포레이티드 | 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법 |
JP2024521748A (ja) | 2021-05-28 | 2024-06-04 | イーライ リリー アンド カンパニー | 潰瘍性大腸炎に関与する遺伝子の抗il-23p19抗体調節 |
KR20230009815A (ko) | 2021-07-09 | 2023-01-17 | 연세대학교 산학협력단 | Il-23에 의해 매개되는 질환의 중증도 예측용 조성물 |
WO2023056417A1 (fr) | 2021-09-30 | 2023-04-06 | Eli Lilly And Company | Régulation d'anticorps anti-il-23p19 de gènes impliqués dans l'urgence intestinale dans la colite ulcéreuse |
WO2024077113A1 (fr) | 2022-10-06 | 2024-04-11 | Eli Lilly And Company | Méthodes de traitement de la fatigue liée à la colite ulcéreuse |
KR20240058012A (ko) | 2022-10-21 | 2024-05-03 | 주식회사 종근당 | 안정한 항체 조성물 |
CN117875575B (zh) * | 2024-03-12 | 2024-05-28 | 中国电子科技集团公司第二十九研究所 | 一种基于混合仿生算法的干扰资源分配方法 |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
WO1981001145A1 (fr) | 1979-10-18 | 1981-04-30 | Univ Illinois | Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
EP0206448B1 (fr) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hémoglobine liée à un poly(oxyde d'alkylène) |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
EP0435911B1 (fr) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (fr) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Vecteurs de transformation de la levure yarrowia |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
JPH08500826A (ja) | 1992-08-21 | 1996-01-30 | ジェネンテク,インコーポレイテッド | Lfa−1仲介疾患を処置する方法 |
EP1005870B1 (fr) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à différentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
CO4810232A1 (es) | 1997-07-25 | 1999-06-30 | Schering Corp | Citoquinas de mamiferos y sus secuencias codificadoras |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
WO1999040195A1 (fr) | 1998-02-06 | 1999-08-12 | Schering Corporation | Proteines de recepteurs de mammiferes; reactifs et procedes apparentes |
WO1999054357A1 (fr) | 1998-04-14 | 1999-10-28 | Chugai Research Institute For Molecular Medicine, Inc. | Nouvelle proteine du type cytokine |
US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
CN100529076C (zh) | 1999-09-09 | 2009-08-19 | 先灵公司 | 哺乳动物细胞因子、相关试剂和方法 |
WO2001085790A2 (fr) | 2000-05-10 | 2001-11-15 | Schering Corporation | Proteines de recepteur de mammifere, reactifs lies et techniques |
US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
WO2003034818A1 (fr) | 2001-10-24 | 2003-05-01 | Chugai Seiyaku Kabushiki Kaisha | Animal non humain a srgf genetiquement modifie |
WO2003039485A2 (fr) | 2001-11-08 | 2003-05-15 | Protein Design Labs | Formulation pharmaceutique liquide stable d'anticorps igg |
EP2108660A1 (fr) | 2002-10-30 | 2009-10-14 | Genentech, Inc. | Inhibition de la production d'il-17 |
AU2003303384A1 (en) | 2002-12-23 | 2004-07-22 | Schering Corporation | Uses of mammalian cytokine; related reagents |
WO2004071517A2 (fr) | 2003-02-06 | 2004-08-26 | Schering Corporation | Utilisations de cytokine de mammifere; reactifs associes |
AU2004219625B9 (en) | 2003-03-10 | 2010-12-23 | Merck Sharp & Dohme Corp. | Uses of IL-23 agonists and antagonists; related reagents |
WO2005005612A2 (fr) | 2003-07-01 | 2005-01-20 | University Of Virginia Patent Foundation | Proteines tag-1 et tag-2 et leurs utilisations |
PT1694360E (pt) | 2003-11-04 | 2010-12-13 | Novartis Vaccines & Diagnostic | Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos |
US20070218060A1 (en) | 2003-11-04 | 2007-09-20 | Chiron Corporation | Use of Antagonist Anti-Cd40 Monoclonal Antibodies for Treatment of Multiple Myeloma |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
ATE533502T1 (de) | 2004-02-17 | 2011-12-15 | Schering Corp | Verfahren zur modulation der il-23-aktivität; relevante reagenzien |
MXPA06012754A (es) | 2004-05-03 | 2007-02-19 | Schering Corp | El uso de la expresion de il-17 para predecir la inflamacion de la piel: metodos de tratamiento. |
US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
AU2005289594B2 (en) | 2004-09-27 | 2012-02-02 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP1853707A2 (fr) | 2004-12-20 | 2007-11-14 | Schering Corporation | Utilisations d'antagonistes il-23 dans le traitement du diabete mellitus |
JP2009500021A (ja) | 2005-06-30 | 2009-01-08 | アーケミックス コーポレイション | サイトカインのil−12ファミリーのポリヌクレオチドおよびポリペプチド |
PT2452694T (pt) | 2005-06-30 | 2019-02-21 | Janssen Biotech Inc | Anticorpos anti-il-23, composições, métodos e utilizações |
DK1937721T3 (da) | 2005-08-25 | 2010-10-18 | Lilly Co Eli | Anti-IL-23 antistoffer |
CN101248088A (zh) * | 2005-08-25 | 2008-08-20 | 伊莱利利公司 | 抗il-23抗体 |
PL1931710T3 (pl) * | 2005-08-31 | 2017-06-30 | Merck Sharp & Dohme Corp. | Przeciwciała anty-il-23 skonstruowane techniką inżynierii genetycznej |
PL1933869T3 (pl) | 2005-09-01 | 2010-06-30 | Merck Sharp & Dohme | Zastosowanie antagonistów IL-23 i IL-17 do leczenia autoimmunologicznej zapalnej choroby oczu |
CN101389769A (zh) | 2005-12-28 | 2009-03-18 | 森托科尔公司 | 用于评价和治疗银屑病及相关疾病的标记与方法 |
PT1971366E (pt) | 2005-12-29 | 2014-11-06 | Janssen Biotech Inc | Anticorpos humanos anti-il-23, composições, métodos e usos |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
CA2655372A1 (fr) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Antagonistes d'il-17 et d'il-23 et leurs procedes d'utilisation |
MX2008015446A (es) | 2006-06-19 | 2008-12-12 | Wyeth Corp | Metodos de modulacion il-22 e il-17. |
MX2009007406A (es) | 2007-01-09 | 2010-01-25 | Wyeth Corp | Formulaciones de anticuerpo anti-il-13 y usos de las mismas. |
TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
AU2008216090A1 (en) | 2007-02-16 | 2008-08-21 | Wyeth | Protein formulations containing sorbitol |
SI2059534T1 (sl) | 2007-02-23 | 2012-08-31 | Schering Corp | Umetno proizvedena anti-il-23p19 antitelesa |
CN101663320A (zh) * | 2007-02-23 | 2010-03-03 | 先灵公司 | 工程改造的抗IL-23p19抗体 |
JP5337055B2 (ja) | 2007-02-28 | 2013-11-06 | メルク・シャープ・アンド・ドーム・コーポレーション | 免疫性障害の処置のための組合せ治療 |
US8871906B2 (en) | 2007-09-04 | 2014-10-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Deletions in domain II of pseudomonas exotoxin a that remove immunogenic epitopes |
AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
CA2703333A1 (fr) | 2007-10-26 | 2009-04-30 | Galderma Research & Development | Procede non invasif pour etudes pharmaco-genomiques de maladies inflammatoires cutanees et leur procede de diagnostic |
CA2607771A1 (fr) | 2007-11-01 | 2009-05-01 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence | Anticorps recombinant humanise contre le virus de l'encephalite equine du venezuela |
TWI543768B (zh) | 2007-11-30 | 2016-08-01 | 艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
WO2009082624A2 (fr) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonistes de il-17a, il-17f et il-23 et procédés d'utilisation de ceux-ci |
WO2010017598A1 (fr) | 2008-08-14 | 2010-02-18 | Arana Therapeutics Limited | Anticorps anti-il-12/il-23 |
CN102202655B (zh) | 2008-08-27 | 2013-06-19 | 默沙东公司 | 基因工程抗IL-23p19抗体的冻干制剂 |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
CA2757237A1 (fr) | 2009-04-01 | 2010-10-14 | Jane Elizabeth Clarkson | Immunoglobulines anti-il-23 |
US20120027799A1 (en) | 2009-04-02 | 2012-02-02 | The Johns Hopkins University | Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer |
US20120269765A1 (en) | 2009-07-24 | 2012-10-25 | Garcia K Christopher | Cytokine compositions and methods of use thereof |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
CN102740888B (zh) | 2009-11-24 | 2016-10-12 | 奥尔德生物制药公司 | Il-6抗体及其用途 |
WO2011069000A2 (fr) | 2009-12-02 | 2011-06-09 | Spartek Medical, Inc. | Prothèse spinale à profil mince incorporant un ancrage osseux ayant un montant déformable et une tige spinale composite |
GB201013975D0 (en) | 2010-08-20 | 2010-10-06 | Imp Innovations Ltd | Method of treating desease |
BR112012019881A2 (pt) | 2010-02-18 | 2017-06-27 | Bristol Myers Squibb Co | proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23 |
EP2538973A2 (fr) | 2010-02-26 | 2013-01-02 | Novo Nordisk A/S | Compositions stables contenant des anticorps |
EP2542221A4 (fr) | 2010-03-01 | 2013-10-23 | Cytodyn Inc | Formulations concentrées de protéine et leurs utilisations |
EP2583098B1 (fr) | 2010-06-15 | 2018-08-08 | Celgene Corporation | Biomarqueurs pour le traitement du psoriasis |
US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
EP2596022A4 (fr) | 2010-07-20 | 2014-11-05 | Cephalon Australia Pty Ltd | Anticorps spécifiques anti-hétérodimère il-23 |
EP2640745B1 (fr) | 2010-09-10 | 2018-11-07 | MedImmune Limited | Anticorps bivalents et bispécifiques dirigés contre il-6 et il-23 |
WO2012061448A1 (fr) | 2010-11-04 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Anticorps anti-il-23 |
GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
TW201309330A (zh) | 2011-01-28 | 2013-03-01 | Abbott Lab | 包含糖基化抗體之組合物及其用途 |
US9078894B2 (en) | 2011-02-04 | 2015-07-14 | Ab Science | Treatment of severe persistant asthma with masitinib |
EP4039275A1 (fr) | 2012-05-03 | 2022-08-10 | Boehringer Ingelheim International GmbH | Anticorps anti-il-23p19 |
US9803010B2 (en) | 2012-06-27 | 2017-10-31 | Merck Sharp & Dohme Corp. | Crystalline anti-human IL-23p19 antibodies |
NZ712294A (en) | 2013-03-15 | 2020-04-24 | Amgen Inc | Methods for treating crohn’s disease using an anti-il23 antibody |
CN105209064A (zh) | 2013-03-15 | 2015-12-30 | 美国安进公司 | 使用抗il-23抗体治疗银屑病的方法 |
KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
TWI711629B (zh) | 2014-09-03 | 2020-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向IL-23A與TNF-α之化合物及其用途 |
CA2972995A1 (fr) | 2015-02-04 | 2016-08-11 | Boehringer Ingelheim International Gmbh | Methodes de traitement de maladies inflammatoires |
MX2018000959A (es) | 2015-07-23 | 2018-06-06 | Boehringer Ingelheim Int | Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos. |
TWI733695B (zh) | 2015-09-18 | 2021-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
-
2011
- 2011-11-02 WO PCT/US2011/058869 patent/WO2012061448A1/fr active Application Filing
- 2011-11-02 CN CN201710917166.3A patent/CN107522784B/zh active Active
- 2011-11-02 SG SG10201604605VA patent/SG10201604605VA/en unknown
- 2011-11-02 SG SG2013031745A patent/SG190006A1/en unknown
- 2011-11-02 CN CN201180064083.5A patent/CN103282382B/zh active Active
- 2011-11-02 EA EA201890548A patent/EA201890548A1/ru unknown
- 2011-11-02 EA EA201300530A patent/EA030436B1/ru active Protection Beyond IP Right Term
- 2011-11-02 PL PL11781949T patent/PL2635601T3/pl unknown
- 2011-11-02 KR KR1020137011474A patent/KR101931591B1/ko active IP Right Grant
- 2011-11-02 MY MYPI2013001519A patent/MY162791A/en unknown
- 2011-11-02 GE GEAP201113106A patent/GEP201706733B/en unknown
- 2011-11-02 HU HUE11781949A patent/HUE030916T2/en unknown
- 2011-11-02 PT PT117819490T patent/PT2635601T/pt unknown
- 2011-11-02 KR KR1020187036509A patent/KR102049223B1/ko active IP Right Grant
- 2011-11-02 BR BR112013011065-1A patent/BR112013011065B1/pt active IP Right Grant
- 2011-11-02 EP EP11781949.0A patent/EP2635601B1/fr active Active
- 2011-11-02 RS RS20160762A patent/RS55161B1/sr unknown
- 2011-11-02 MX MX2013005015A patent/MX343858B/es active IP Right Grant
- 2011-11-02 SI SI201130958A patent/SI2635601T1/sl unknown
- 2011-11-02 CA CA3017116A patent/CA3017116A1/fr not_active Abandoned
- 2011-11-02 CA CA2816950A patent/CA2816950C/fr active Active
- 2011-11-02 EP EP17179739.2A patent/EP3281954A1/fr not_active Withdrawn
- 2011-11-02 MX MX2016015419A patent/MX362039B/es unknown
- 2011-11-02 NZ NZ610592A patent/NZ610592A/en unknown
- 2011-11-02 EP EP18188208.5A patent/EP3456740A1/fr not_active Withdrawn
- 2011-11-02 PE PE2013000951A patent/PE20141162A1/es active IP Right Grant
- 2011-11-02 DK DK11781949.0T patent/DK2635601T3/en active
- 2011-11-02 JP JP2013537771A patent/JP6126532B2/ja active Active
- 2011-11-02 ES ES11781949.0T patent/ES2593754T3/es active Active
- 2011-11-02 MX MX2019000046A patent/MX2019000046A/es unknown
- 2011-11-02 US US13/287,208 patent/US8778346B2/en active Active
- 2011-11-02 AU AU2011323426A patent/AU2011323426B2/en active Active
- 2011-11-02 EP EP16178404.6A patent/EP3115375A1/fr not_active Withdrawn
- 2011-11-02 LT LTEP11781949.0T patent/LT2635601T/lt unknown
- 2011-11-02 AP AP2013006820A patent/AP3953A/en active
- 2011-11-03 AR ARP110104094A patent/AR083747A1/es active IP Right Grant
- 2011-11-03 TW TW100140204A patent/TWI545133B/zh active
- 2011-11-03 UY UY0001033703A patent/UY33703A/es active IP Right Grant
- 2011-11-03 TW TW105114183A patent/TWI653242B/zh active
-
2012
- 2012-11-02 ME MEP-2016-176A patent/ME02499B/fr unknown
-
2013
- 2013-04-09 IL IL225648A patent/IL225648A/en active Protection Beyond IP Right Term
- 2013-05-02 MA MA35866A patent/MA34641B1/fr unknown
- 2013-05-24 CO CO13128280A patent/CO6801628A2/es active IP Right Grant
- 2013-05-30 EC ECSP13012649 patent/ECSP13012649A/es unknown
- 2013-11-20 HK HK18107343.9A patent/HK1247940A1/zh unknown
-
2014
- 2014-06-12 US US14/302,986 patent/US9441036B2/en active Active
-
2016
- 2016-02-29 IL IL244335A patent/IL244335A/en active Protection Beyond IP Right Term
- 2016-08-04 US US15/228,254 patent/US10202448B2/en active Active
- 2016-09-06 HR HRP20161141TT patent/HRP20161141T1/hr unknown
- 2016-09-13 CY CY20161100899T patent/CY1118014T1/el unknown
- 2016-12-16 AU AU2016273970A patent/AU2016273970B2/en active Active
-
2017
- 2017-01-13 JP JP2017003955A patent/JP6445596B2/ja active Active
-
2018
- 2018-09-24 AU AU2018236692A patent/AU2018236692C1/en active Active
- 2018-11-29 JP JP2018223469A patent/JP6758361B2/ja active Active
-
2019
- 2019-01-25 US US16/257,463 patent/US20190144534A1/en not_active Abandoned
- 2019-10-14 LU LU00132C patent/LUC00132I2/fr unknown
- 2019-10-14 HU HUS1900048 patent/HUS1900048I1/hu unknown
- 2019-10-15 LT LTPA2019518C patent/LTC2635601I2/lt unknown
- 2019-10-16 NL NL301013C patent/NL301013I2/nl unknown
- 2019-10-17 NO NO2019038C patent/NO2019038I1/no unknown
- 2019-10-17 CY CY2019040C patent/CY2019040I1/el unknown
-
2020
- 2020-10-09 US US17/066,994 patent/US20210198355A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1900048I1 (hu) | Anti-IL-23 antitestek | |
HRP20180952T1 (hr) | Anti-dll3 antitijelo | |
ZA201209004B (en) | Anti-fgfr2 antibodies | |
GB201000467D0 (en) | Antibodies | |
IL221371A0 (en) | Anti-lrp6 antibodies | |
PT2581113T (pt) | Anticorpo anti-tim-3 | |
PL2616489T3 (pl) | Przeciwciało anty-huTNFR1 | |
IL225667A0 (en) | A new antigen | |
EP2596022A4 (fr) | Anticorps spécifiques anti-hétérodimère il-23 | |
HK1194388A1 (zh) | 抗缺刻蛋白 抗體 | |
PT2603528T (pt) | Anticorpos glicosilados em fab | |
GB201020738D0 (en) | Antibodies | |
GB201002238D0 (en) | Antibodies | |
ZA201302459B (en) | Antibodies | |
GB201007957D0 (en) | Antibody | |
GB201020751D0 (en) | Antibodies | |
GB201005062D0 (en) | Antibodies | |
GB201017780D0 (en) | Antibody |